Left ventricular function and morphology were assessed using M-modeechocardiography in 3 patients with diabetes mellitus associated with mitochondrial tRNALeu(UUR) gene mutation, who were free of clinical, electrocardiographic, or thallium scan evidence of ischemic heart disease. Echocardiograms revealed hypertrophic cardiomyopathy in all 3 patients. Hypertrophy of the interventricular septum was mild in Cases 1 and 3 (12 and 13 mm,respectively) and severe in Case 2 (22 mm)(normal 7-10 mm). Whenthey had neither signs nor symptoms suggestive ofcongestive heart failure, percentage fractional shortening ( %FS), an index of wall motion of the left ventricle (normal >28%), was normal in Cases 2 and 3 (28 and 32%, respectively) whereas it was slightly decreased in Case 1 (22%). In Case 1 with mild hypertrophy, the development ofcongestive heart failure was associated with a marked decrease in %FSto 13%; this patient responded well to diuretics and captopril and %FSrose to 22%. However, a mild decrease in %FSto 21%caused congestive heart failure in Case 2 with severe hypertrophy. His response to treatment was marginal. The present study indicates that mitochondrial DNAanalysis should be done in patients with diabetic cardiomyopathy, and that sequential echocardiography is invaluable for the detection of hypertrophic cardiomyopathy and the managementof subsequent myocardial dysfunction in patients with mitochondrial diabetes mellitus and cardiomyopathy. (Internal Medicine 34: 953-958, 1995) 
Introduction
Clinical, epidemiologic and pathologic data support the presence of specific cardiomyopathy related to diabetes mellitus (1, 2) . The existence of diabetic cardiomyopathy was first suggested by Rubier et al (3) on the basis of postmortem findings in diabetic adults with congestive heart failure. The diagnosis of diabetic cardiomyopathy can be entertained only after the exclusion of coronary artery disease and other conditions such as hypertension, known to cause myocardial dysfunction. On the other hand, a striking increase in the incidence of congestive heart failure has been reported in patients with diabetes mellitus (4) . The present studies have demonstrated hypertrophic cardiomyopathy in 3 patients with long-standing diabetes mellitus associated with a point mutation of mitochondrial DNA.We also describe their clinical course and the utility of echocardiography in the detection of subsequent myocardial dysfunction.
Patients and Methods

Pa tien ts
Clinical features and laboratory data are summarized in Tables 1 and 2 . The 3 patients were short in stature, lean, hypolipidemic and were not hypertensive. In Cases 1 and 3, as previously reported (5) and poor glycemic control in Cases 1 and 3, diabetic microvascular complication was not observed in 2 cases and was very mild in the other case. Bilateral sensorineural hearing loss was confirmed in all of them. However, they lacked symptoms and signs suggestive of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). As previously reported (5), Cases 1 and 3 had low responses not only of C-peptide to a glucagon injection but also of pancreatic glucagon to an arginine infusion, showing dysfunction of B cells as well as A cells.
Mitochondrial DNAanalysis
This was done as previously reported (5) . In brief, using mitochondrial DNAextracts from patients ' platelets, we amplified the region encoding tRNAs by polymerase chain reaction and sequenced it. In Case 1, biopsy specimens were obtained, Ech o ca rdiograp hy M-mode echocardiograms of the left ventricle were obtained using an ultrasound system (Toshiba Corp., Tokyo, Japan) and a 3.5-MHz transducer. Those were performed at rest with the patient at a steady state in the left lateral position. We measured the thickness of the interventricular septum (IVS) and left ventricular posterior wall at the left ventricular minor axis at the level of the chordae tendinaejust beyond the mitral leaflet tips, as recommendedby the American Society of Echocardiography (6). Every effort was made to obtain optimal echocardiographic images, with the M-modecursor perpendicular to the left ventricular long axis. End-diastolic and endsystolic dimensions of the left ventricle (LVDd and LVDs, respectively) were also measured. Percentage fractional shortening (%FS), an index of wall motion of the left ventricle, was calculated as follows:
Thallium-20 1 exercise myocardial perfusion scintigraphy. Thallium-201 (3 mCi) was injected i.v. at the time of maximal stress during a multistage treadmill test according to the Bruce protocol (7). Single photon emission computed tomography (SPECT) images were obtained with a wide-field-of-view rotating gammacamera equipped with a long-energy, highresolution, parallel-hole collimator (Toshiba GC 90A, Tokyo, Japan). The SPECTimages were acquired at the 80 KeV photopeak ofthallium-201 with a symmetric 10% window. The early and delayed images were obtained 5 minutes and 3 hours after a thallium injection, respectively. Results AnA-to-G transition at nucleotide 3243 was identified in mitochondrial DNAfrom platelets in all patients. In Case 1 , the proportion of mutant mitochondrial DNAwas 60%in right ventricular endomyocardial biopsy specimens, whereas it was 24% in platelets, 50% in the stomach, 54%in the rectum and 43% in the urinary bladder (Fig. 1) . There was no mutation other than the transition at 3243 between position 3230 and 3304.
Case 1 underwent echocardiography because of systolic murmur at age 56 (April 1990), when he received treatment for diabetes mellitus for the first time. Although he had neither signs nor symptoms suggestive of congestive heart failure, echocardiograms had revealed low %FSof 22%, thickening of the left-ventricular wall, and mild mitral regurgitation, the last of which was the cause of systolic murmur (Table 3) . Exercise electrocardiogram (ECG) revealed no ischemic response and his chest radiograph was normal. He was diagnosed with diabetic cardiomyopathy. At age 59, he was admitted to the hospital because of congestive heart failure, which was associated with a further decrease of %FSand an increase of cardiothoracic ratio (CTR). Mitochondrial DNAanalysis revealed the 3243 mutation. He responded well to treatment with diuretics and captopril. After 2 months of the treatment, his CTRdecreased to 43% (Fig. 2) , and his %FSrose to 22% (Fig. 3) . Coronary angiography revealed no significant stenosis. Right ventricular endomyocardial biopsy revealed no remarkable findings except for vacuolation around the nucleus ofmyocytes.
Severe hypertrophic cardiomyopathy (Fig. 4) was detected, at age 74, in Case 2 with diabetes of 27 years' duration and taking an oral hypoglycemic agent. However, his %FS(28%), ECGand chest radiograph were normal. He was diagnosed as having idiopathic hypertrophic cardiomyopathy and/or diabetic cardiomyopathy.
Three years later, he complained of exertional dyspnea. This was associated with cardiac enlargement with a CTR of52% and a slight decrease of %FS to 21% from 28%. His CTR could not be restored with treatment with diuretics and inhibitors of angiotension converting enzymes. The 3243 mutation was demonstrated in his platelet DNA. The third case was a 43-year-old man whowas shown to have the 3243 mutation associated with diabetes of 26 years' Figure 2 . Chest radiographs in a 59-year-old male (Case 1) with diabetes mellitus, deafness, and hypertrophic cardiomyopathy associated with a point mutation of mitochondrial DNA. Cardiac enlargement with a CTR of66% and pleural effusion was found in October 1993 (left), at the time of complaints of orthostatic dyspnea and edema, and disappeared after 2 months of treatment with diureties and captopril (December 1993, right). He lost 13 kg body weight and his CTRdecreased to 47%.
duration on insulin. He showed mild cardiac hypertrophy on echocardiograms, although his ECG, chest radiograph and %FSof 32%were normal. He never had signs or symptoms suggestive of congestive heart failure. Exercise myocardial perfusion scintigraphy with thallium-201 showed no defects in Cases 1 and 3. Case 2 refused it.
Discussion
An A-to-G transition at position 3243 in the mitochondrial tRNALeu(UUR)gene was originally identified in patients with MELASsyndrome (8). This mutation was subsequently found in patients with diabetes mellitus and deafness (9, 10) as well as in those with cardiomyopathy (ll, 12). The present study employing echocardiography, demonstrated hypertrophic cardiomyopathy in 3 patients with diabetes mellitus and deafness associated with the 3243 mutation. This observation may be consistent with a recent finding that cardiomyopathy was found in 4 patients with MELAS, whose age ranged from 10 to 19 years old (13) . Because different point mutations and deletions of mitochondrial DNAhave been reported in patients with hypertrophic cardiomyopathy (1 1, 14, 15) , genetic mitochondrial dysfunction may be of pathogenic importance in the development of myocardial hypertrophy. The presence of specific cardiomyopathy related to diabetes mellitus, diabetic cardiomyopathy, is supported by epidemiologic, clinical and pathologic data (1, 2). The diagnosis of diabetic cardiomyopathy should be made only after the exclusion of atherosclerotic and hypertensive heart disease and other conditions known to cause myocardial dysfunction. When ECGrevealed no ischemic response. Furthermore, they had no conditions other than long-standing diabetes mellitus, such as alcohol abuse, valvular disease, congenital heart disease, pericardial disease, thyroid disorders, or pericarditis, known to cause myocardial dysfunction. Therefore, they had been diagnosed as having diabetic cardiomyopathy. Three years later, mitochondrial DNAanalysis became available for clinical use and an A-to-G transition at position 3243 in the mitochondrial tRNALeu(UUR) was subsequently identified in these 2 patients.
These observations indicate that mitochondrial DNAmutation should be examined in diabetic patients with cardiomyopathy. The FraminghamHeart Study suggests a causal role of diabetes mellitus in the development of congestive heart failure (4). In this prospective study over an 1 8-year-follow-up period, the frequency of congestive heart failure was more than twice as high in diabetic men than in the nondiabetic cohort. This excessive risk persisted even whentaking into account age, hypertension, obesity and hypercholesterolemia, factors which commonlycoexist with long-standing diabetes mellitus. The excessive risk of congestive heart failure was confined to diabetic individuals with hyperglycemia severe enough to warrant insulin therapy, whereas patients treated with diet therapy or oral hypoglycemic agents had no increased risk of congestive heart failure (4). In the present studies, 2 diabetic patients with congestive heart failure were lean, hypo- cholesterolemic and not hypertensive and have been treated with an oral hypoglycemic agent. These findings suggest that congestive heart failure found in these 2 patients was not secondary to diabetic cardiomyopathy but was associated with hypertrophic cardiomyopathy due to an A-to-G transition in the mitochondrial tRNALeu(UUR).
It is noted that ultrasound examination of the heart in Case 1 revealed cardiac hypertrophy and left ventricular dysfunction indicated by low %FS, even when his ECGand chest radiograph were normal. Three years later, he developed congestive heart failure. This was associated with a 9% decrease in %FS (from 22 to 13%) and an increase in CTR. His ECGand chest radiograph, however, were normal after 2 months of treatment with diuretics and captopril; %FSrose to 22% and CTRrestored to normal. These findings, coupled with the observation that, as mentioned earlier, myocardial hypertrophy is found in patients with various forms of genetic mitochondrial dysfunction, suggest that patients with mitochondrial DNAmutation should undergo echocardiography even if the ECGand chest radiograph are normal.
A portion of this work has been described in Letters to the Lancet (16).
